Package 25021-230-05

{"route": ["INTRAVENOUS"], "spl_id": "beff4b0b-e884-4134-ba9e-290020a94add", "openfda": {"unii": ["042LAQ1IIS"], "rxcui": ["1726319", "1726324"], "spl_set_id": ["caab50e6-0dad-4ddd-9a6c-96cc2b87aee7"], "manufacturer_name": ["Sagent Pharmaceuticals"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL in 1 CARTON (25021-230-02)  / 2 mL in 1 VIAL", "package_ndc": "25021-230-02", "marketing_end_date": "20261031", "marketing_start_date": "20140815"}, {"sample": false, "description": "1 VIAL in 1 CARTON (25021-230-05)  / 5 mL in 1 VIAL", "package_ndc": "25021-230-05", "marketing_end_date": "20260831", "marketing_start_date": "20140815"}], "brand_name": "Irinotecan Hydrochloride", "product_id": "25021-230_beff4b0b-e884-4134-ba9e-290020a94add", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Topoisomerase Inhibitor [EPC]", "Topoisomerase Inhibitors [MoA]"], "product_ndc": "25021-230", "generic_name": "irinotecan hydrochloride", "labeler_name": "Sagent Pharmaceuticals", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Irinotecan Hydrochloride", "active_ingredients": [{"name": "IRINOTECAN HYDROCHLORIDE", "strength": "20 mg/mL"}], "application_number": "ANDA090675", "marketing_category": "ANDA", "marketing_end_date": "20261031", "marketing_start_date": "20140815"}